BioSpace News Archive

The Ontario Bioscience Innovation Organization (OBIO®) is proud to announce the opening of the Canadian Health Investment Showcase in New York, NY, on November 5 and 6, 2018.

Wearing red has become a popular way to support the prevention of heart disease, the #1 killer of women. Now new research suggests eating red may be one of the best ways to keep your heart healthy.

On October 11, in conjunction with Hospice of Marion County’s “Uptown Hoedown” Gala and fundraiser, Florida Hospice & Palliative Care Association presented Rep. Charlie Stone (R), Ocala, with a “2018 Hospice Champion Award.”

IBM Watson Health™ (NYSE: IBM) today published its 50 Top Cardiovascular Hospitals™ annual study identifying top U.S. hospitals for inpatient cardiovascular services based on a balanced national scorecard of hospital performance metrics.

“I conceived of this invention due to the amount of time I have spent in hospitals,” said an inventor from Euless, Texas. “This inspired me to develop a better bedside table that could make life easier for patients as well as nurses.”

DiamiR, a developer of innovative, minimally invasive diagnostic tests for neurodegenerative and other diseases, announced today two publications in Aging:

Many breast imaging centers have launched high risk screening clinics to augment their existing services

Luminex Corporation (Nasdaq: LMNX) today announced financial results for the third quarter of 2018. Financial and operating highlights for the quarter include:

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today reported financial results for the third quarter ended September 30, 2018 and provided a review of recent business and clinical highlights.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its third quarter 2018 financial results and provided an update on the company and its progress with IPI-549, a first-in-class oral immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase-gamma